Literature DB >> 24961987

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

John T Reilly1, Mary Frances McMullin, Philip A Beer, Nauman Butt, Eibhlin Conneally, Andrew S Duncombe, Anthony R Green, George Mikhaeel, Marie H Gilleece, Steven Knapper, Adam J Mead, Ruben A Mesa, Mallika Sekhar, Claire N Harrison.   

Abstract

Entities:  

Keywords:  CALR; JAK inhibition; myeloproliferative disease

Mesh：

Substances：

Year:  2014        PMID： 24961987     DOI： 10.1111/bjh.12985

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  16 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.

Authors:  Martin H Ellis; Maya Koren-Michowitz; Noa Lavi; Alessandro M Vannucchi; Ruben Mesa; Claire N Harrison
Journal:  Leuk Res       Date:  2017-08-10       Impact factor: 3.156

Review 3.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

Review 4.  A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.

Authors:  Ros Wade; Robert Hodgson; Mousumi Biswas; Melissa Harden; Nerys Woolacott
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

5.  Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Authors:  Thamer Sliwa; Christine Beham-Schmid; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Maria Krauth; Peter Krippl; Alois Lang; Andreas Petzer; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2016-12-13       Impact factor: 1.704

6.  Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Authors:  Claire N Harrison; Nicolaas Schaap; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Ramon V Tiu; Pierre Zachee; Eric Jourdan; Elliott Winton; Richard T Silver; Harry C Schouten; Francesco Passamonti; Sonja Zweegman; Moshe Talpaz; Joanne Lager; Zhenming Shun; Ruben A Mesa
Journal:  Lancet Haematol       Date:  2017-06-08       Impact factor: 18.959

7.  Methotrexate Is a JAK/STAT Pathway Inhibitor.

Authors:  Sally Thomas; Katherine H Fisher; John A Snowden; Sarah J Danson; Stephen Brown; Martin P Zeidler
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

8.  Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.

Authors:  K Shide; T Kameda; T Yamaji; M Sekine; N Inada; A Kamiunten; K Akizuki; K Nakamura; T Hidaka; Y Kubuki; H Shimoda; A Kitanaka; A Honda; A Sawaguchi; H Abe; T Miike; H Iwakiri; Y Tahara; M Sueta; S Hasuike; S Yamamoto; K Nagata; K Shimoda
Journal:  Leukemia       Date:  2016-11-03       Impact factor: 11.528

9.  Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Authors:  Jacob Grinfeld; Jyoti Nangalia; E Joanna Baxter; David C Wedge; Nicos Angelopoulos; Robert Cantrill; Anna L Godfrey; Elli Papaemmanuil; Gunes Gundem; Cathy MacLean; Julia Cook; Laura O'Neil; Sarah O'Meara; Jon W Teague; Adam P Butler; Charlie E Massie; Nicholas Williams; Francesca L Nice; Christen L Andersen; Hans C Hasselbalch; Paola Guglielmelli; Mary F McMullin; Alessandro M Vannucchi; Claire N Harrison; Moritz Gerstung; Anthony R Green; Peter J Campbell
Journal:  N Engl J Med       Date:  2018-10-11       Impact factor: 91.245

10.  MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

Authors:  K Kollmann; J Nangalia; W Warsch; H Quentmeier; A Bench; E Boyd; M Scott; H G Drexler; A R Green
Journal:  Leukemia       Date:  2014-09-24       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.